Efficacy of Atezolizumab in Subsequent Lines of Therapy for NSCLC Patients: Insights from Real-World Data.

IF 4.5 2区医学 Q1 ONCOLOGY

Cancers Pub Date : 2024-11-01 DOI:10.3390/cancers16213696

Milica Kontić, Filip Marković, Nikola Nikolić, Natalija Samardžić, Goran Stojanović, Petar Simurdić, Svetlana Petkov, Daliborka Bursać, Bojan Zarić, Mihailo Stjepanović

{"title":"Efficacy of Atezolizumab in Subsequent Lines of Therapy for NSCLC Patients: Insights from Real-World Data.","authors":"Milica Kontić, Filip Marković, Nikola Nikolić, Natalija Samardžić, Goran Stojanović, Petar Simurdić, Svetlana Petkov, Daliborka Bursać, Bojan Zarić, Mihailo Stjepanović","doi":"10.3390/cancers16213696","DOIUrl":null,"url":null,"abstract":"Immune checkpoint inhibitors (ICIs) like atezolizumab have improved outcomes in advanced non-small cell lung cancer (NSCLC) patients, especially in the second-line setting after progression on platinum-based chemotherapy. However, access to ICIs remains limited in many developing nations. This study evaluated the efficacy of atezolizumab as a second-line versus later-line treatment for advanced NSCLC patients in Serbia.Methods: This retrospective study involved 147 advanced NSCLC patients treated with atezolizumab following progression on prior platinum-based chemotherapy at two academic centers in Serbia. Data on demographics and clinical, pathological, and molecular characteristics were collected. Median progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and multivariable Cox proportional hazards regression identified outcome predictors.Results: The median PFS was 7.13 months, and median OS was 38.6 months. The overall response rate (ORR) was 15%, with a disease control rate (DCR) of 57.9%. No significant PFS differences were observed between patients treated with atezolizumab in the second line versus later lines. Patients with good performance status (ECOG 0-1) had significantly better PFS compared to those with poorer status (12.03 vs. 1.63 months, p < 0.0001).Conclusions: Atezolizumab is effective in both second-line and later-line settings for advanced NSCLC, particularly in patients with good performance status. This highlights the importance of patient selection based on performance status, as well as the need for wider access to ICIs in resource-limited regions.","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 21","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11545278/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers16213696","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Immune checkpoint inhibitors (ICIs) like atezolizumab have improved outcomes in advanced non-small cell lung cancer (NSCLC) patients, especially in the second-line setting after progression on platinum-based chemotherapy. However, access to ICIs remains limited in many developing nations. This study evaluated the efficacy of atezolizumab as a second-line versus later-line treatment for advanced NSCLC patients in Serbia.

Methods: This retrospective study involved 147 advanced NSCLC patients treated with atezolizumab following progression on prior platinum-based chemotherapy at two academic centers in Serbia. Data on demographics and clinical, pathological, and molecular characteristics were collected. Median progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and multivariable Cox proportional hazards regression identified outcome predictors.

Results: The median PFS was 7.13 months, and median OS was 38.6 months. The overall response rate (ORR) was 15%, with a disease control rate (DCR) of 57.9%. No significant PFS differences were observed between patients treated with atezolizumab in the second line versus later lines. Patients with good performance status (ECOG 0-1) had significantly better PFS compared to those with poorer status (12.03 vs. 1.63 months, p < 0.0001).

Conclusions: Atezolizumab is effective in both second-line and later-line settings for advanced NSCLC, particularly in patients with good performance status. This highlights the importance of patient selection based on performance status, as well as the need for wider access to ICIs in resource-limited regions.

查看原文本刊更多论文

Atezolizumab在NSCLC患者后续治疗中的疗效：真实世界数据的启示

阿特珠单抗等免疫检查点抑制剂（ICIs）改善了晚期非小细胞肺癌（NSCLC）患者的治疗效果，尤其是在铂类化疗进展后的二线治疗中。然而，在许多发展中国家，获得 ICIs 的机会仍然有限。本研究评估了阿特珠单抗作为塞尔维亚晚期NSCLC患者二线治疗与后线治疗的疗效：这项回顾性研究涉及塞尔维亚两所学术中心的 147 名晚期 NSCLC 患者，他们在之前接受铂类化疗后病情恶化，并接受了阿特珠单抗治疗。研究人员收集了人口统计学数据以及临床、病理和分子特征。采用Kaplan-Meier方法估算了中位无进展生存期（PFS）和总生存期（OS），并通过多变量Cox比例危险回归确定了结果预测因素：中位PFS为7.13个月，中位OS为38.6个月。总反应率（ORR）为 15%，疾病控制率（DCR）为 57.9%。接受阿特珠单抗二线治疗的患者与接受后线治疗的患者在PFS上没有明显差异。表现状态良好（ECOG 0-1）的患者的PFS明显优于表现状态较差的患者（12.03个月对1.63个月，P < 0.0001）：Atezolizumab在晚期NSCLC的二线和三线治疗中均有效，尤其是对表现良好的患者。这凸显了根据表现状态选择患者的重要性，以及在资源有限的地区更广泛地使用 ICIs 的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancers Medicine-Oncology

CiteScore

8.00

自引率

9.60%

发文量

5371

审稿时长

18.07 days

期刊介绍： Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.